Torthaí cuardaigh - Arndt Vogel
- 1 - 20 toradh as 125 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Autoimmune Hepatitis, From Mechanisms to Therapy de réir Michael P. Manns, Arndt Vogel
Foilsithe / Cruthaithe 2006Revisão -
2
Epidemiology and Risk Factors of Cholangiocarcinoma de réir Martha M. Kirstein, Arndt Vogel
Foilsithe / Cruthaithe 2016Artigo -
3
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? de réir Anna Saborowski, Ulrich Lehmann, Arndt Vogel
Foilsithe / Cruthaithe 2020Revisão -
4
-
5
FGFR2 Inhibition in Cholangiocarcinoma de réir Arndt Vogel, Oreste Segatto, Albrecht Stenzinger, Anna Saborowski
Foilsithe / Cruthaithe 2022Revisão -
6
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies de réir Arndt Vogel, Ralf‐Dieter Hofheinz, Stefan Kubicka, Dirk Arnold
Foilsithe / Cruthaithe 2017Revisão -
7
The Diagnosis and Treatment of Cholangiocarcinoma de réir Arndt Vogel, Henning Wege, Karel Caca, Björn Nashan, Ulf P. Neumann
Foilsithe / Cruthaithe 2014Revisão -
8
Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice de réir Ângelo Zambam de Mattos, Isadora Bombassaro, Arndt Vogel, José D. Debes
Foilsithe / Cruthaithe 2024Artigo -
9
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab de réir Chiun Hsu, Lorenza Rimassa, Hui‐Chuan Sun, Arndt Vogel, Ahmed O. Kaseb
Foilsithe / Cruthaithe 2021Revisão -
10
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma de réir Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel
Foilsithe / Cruthaithe 2022Artigo -
11
Systemic Therapy of Advanced Hepatocellular Carcinoma de réir Peter R. Galle, Jean‐François Dufour, Markus Peck‐Radosavljevic, Jörg Trojan, Arndt Vogel
Foilsithe / Cruthaithe 2020Revisão -
12
UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer de réir Johann Ockenga, Arndt Vogel, Niels Teich, Volker Keim, Michael P. Manns, Christian P. Strassburg
Foilsithe / Cruthaithe 2003Artigo -
13
-
14
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing de réir Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Ángela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Foilsithe / Cruthaithe 2023Revisão -
15
-
16
Next-Generation Biomarkers for Cholangiocarcinoma de réir Pedro M. Rodrigues, Arndt Vogel, Marco Arrese, Domingo Balderramo, Juan W. Valle, Jesús M. Bañales
Foilsithe / Cruthaithe 2021Revisão -
17
Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy de réir Ângelo Zambam de Mattos, José D. Debes, André Boonstra, Arndt Vogel, Ângelo Alves de Mattos
Foilsithe / Cruthaithe 2021Revisão -
18
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up de réir Florian Lordick, Fátima Carneiro, Stefano Cascinu, Tania Fleitas, Karin Haustermans, Guillaume Piessen, Arndt Vogel, Elizabeth Smyth
Foilsithe / Cruthaithe 2022Artigo -
19
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines de réir Arndt Vogel, Erika Martinelli, Arndt Vogel, Andrés Cervantes, Ian Chau, Bruno Daniele, Josep M. Llovet, Tim Meyer, Jean‐Charles Nault, Ulf P. Neumann, Jens Ricke, Bruno Sangro, Peter Schirmacher, Chris Verslype, Francis Zech, Dirk Arnold, Erika Martinelli
Foilsithe / Cruthaithe 2021Artigo -
20
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer de réir Ansgar Lange, Anne Prenzler, Martin Frank, Martha M. Kirstein, Arndt Vogel, Johann‐Matthias Graf von der Schulenburg
Foilsithe / Cruthaithe 2013Revisão
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Internal medicine
Oncology
Hepatocellular carcinoma
Cancer
Gastroenterology
Biology
Chemotherapy
Immunotherapy
Cancer research
Genetics
Pathology
Adverse effect
Gene
Sorafenib
Bevacizumab
Disease
Cirrhosis
Immunology
Biochemistry
Nivolumab
Surgery
Atezolizumab
Clinical trial
Cohort
Cell biology
Confidence interval
Environmental health
Population
Pembrolizumab